Recent Headlines
Within Biotechnology
MacroArray Diagnostics GmbH (MADx) Partners with ALPCO to Offer a Fully Automated Sample-to-Answer Multiplex Allergy Test Solution to the North American Market
ALPCO (Salem, NH), a leading US producer of novel immunoassay testing platforms, recently announced an exclusive distribution partnership with MacroArray Diagnostics GmbH (Vienna, Austria). Together, they offer a comprehensive line of testing solutions for allergies (IgE-based) and food intolerances (IgG-based), from test material to proprietary hardware and software to process and analyze samples. - February 01, 2022 - ALPCO
Jubilance, Clinically-Proven PMS Relief Supplement, Gets Makeover for 2022
Women's Wellness company Jubilance offers suite of free wellness resources to help women feel their best all month long. Resources include therapist-designed guided meditations for specific PMS symptoms, a PMS research library, curated women's health guides, podcasts, playlists and more. Clinically proven PMS relief supplement Jubilance announces new label makeover for 2022 to better reflect that jubilant feeling of freedom from PMS anxiety, gloominess, stress and irritability. - January 26, 2022 - Jubilance for PMS
NuvOx to Present at Various Bio Forums in JPM Week
NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, will participate in various Bio forums held Jan 10 – 14, 2022. Dr. Evan Unger, NuvOx’s Chief Executive Officer, is presenting in... - January 14, 2022 - NuvOx Therapeutics
PharmStars Now Accepting Applications for Spring 2022 Accelerator Program; Startups with Digital Innovations in Neurological Disease Are Welcome to Apply
PharmStars, the pharma-focused accelerator for digital health startups, is now accepting applications for its spring 2022 cohort with the theme, “Digital Innovations in Neurological Disease.” - January 04, 2022 - PharmStars
Global Regenerative Academy Announces Prof. Tahsin Beyzadeoglu as President
Global Regenerative Academy, independent subsidiary of the Global Regenerative Group Inc., has new board leadership. GRA President is now Prof. Tahsin Beyzadeoglu as announced during the opening Ceremony of GRC Dubai 2021 (November 19-21, 2021) by Mr. Mihail Blagoev (GRG Inc. VP) after being elected by the Scientific Board. - December 21, 2021 - Global Regenerative Group
Mirror Biologics, Inc. Announces Close of a $14 Million Financing Round
This Funding will be Used, in Part, to Launch an Asian Phase II/III Randomized Controlled Registration Trial for Advanced Liver Cancer in Q1/2-2022. - December 09, 2021 - Mirror Biologics, Inc.
PharmStars Announces 2021 Accelerator Graduates
12 digital health startups have successfully completed PharmStars’ inaugural 10-week pharma-focused accelerator program. - December 08, 2021 - PharmStars
Doubling Down: HCPA Panel Selects Locus Performance Ingredients for Two Innovation Awards at XPAND2021
Green Tech Start-Up Recognized for Advancing Sustainable Cleaning Products with High-Performance Biosurfactant Ingredients and Carbon-Neutral Production Process. - December 08, 2021 - Locus Performance Ingredients
Pelvic Floor HIFEM (Emsella) Improves the Intensity and Duration of Male Orgasm
Dr. Judson Brandeis studied the Emsella, a device that has been FDA-approved for the treatment of urinary incontinence by stimulating the pelvic floor muscles, in mid-life men with weak or delayed ejaculation. He discovered that four weekly thirty-minute treatments with the Emsella protocol 2 was enough to improve the self-reported intensity and duration of ejaculation. - November 30, 2021 - BrandeisMD
Parvus Therapeutics Announces Development and Manufacturing Agreement with Resilience to Advance Novel Autoimmune Drug Candidate PVT201
Parvus Therapeutics, a biopharmaceutical company developing Navacim™ platform-based disease-specific immunoregulator therapeutics to treat autoimmune diseases by activating endogenous generation of disease-specific regulatory T cells (Tregs) without impairing normal immune system function,... - November 29, 2021 - Parvus Therapeutics U.S., Inc.
LPA Statement Regarding Voxzogo™
Little People of America (LPA), the world’s oldest and largest support organization for people with dwarfism and their families, has been tracking biotechnical developments for the treatment of individuals with Achondroplasia. LPA President, Mark Povinelli, says, "With the FDA approval... - November 21, 2021 - Little People of America Inc.
Parvus Therapeutics and Ardena Enter Agreement for Tech Transfer, Scale-Up and GMP Manufacturing of Navacim Nanoparticles
Today Parvus announced it has entered into an agreement with Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO), for process development, scale-up and GMP manufacturing of NavacimTM nanoparticles, a key building block for all of our Navacim platform drug development candidates. - November 19, 2021 - Parvus Therapeutics U.S., Inc.
CANNA/Hemp Extraction Labs USA Announces Joint Venture Partnerships for Cannabis Cultivators/Growers and Cannapreneurs
CANNA/Hemp Extraction Labs USA (CHELUSA) announced today they are offering to finance and commission Cannabis Extraction Labs and Cannabis Cloning Labs in NM, NJ, AZ, IL, MT and VA. CHELUSA is looking to form strategic partnerships with Cultivators/Growers and Cannapreneurs in these key states. The... - November 18, 2021 - Hemp Extraction Labs USA
PharmStars Announces Showcase Event for Inaugural Class
PharmStars, a pharma-focused accelerator for digital health startups, announces the start of its 2021 Showcase Event. At the Showcase Event, the 12 startups in the accelerator’s current cohort will pitch their digital health solutions to PharmStars’ pharma members. The startups and pharma members will also have the opportunity to meet privately to discuss potential partnership opportunities. - November 17, 2021 - PharmStars
Mirror Biologics Announces Issuance of US Patent Covering Next Generation Therapeutic Vaccine Technology for Treatment of Cancer and Infectious Disease
Mirror Biologics, Inc., a private clinical stage biopharmaceutical company, today announces the issuance of US Patent No. 11,160,852, “Method of Vaccinating Using Allogeneic Cells,” covering methods for creating a next generation of therapeutic vaccines against cancers and infectious... - November 17, 2021 - Mirror Biologics, Inc.
PharmStars Welcomes Sumitovant Biopharma as Its Newest Member
PharmStars, the only pharma-focused, member-based accelerator for digital health startups, is pleased to announce that Sumitovant Biopharma has become its newest pharma member, joining existing members including Boehringer Ingelheim, Eli Lilly and Company, and Novo Nordisk. PharmStars focuses on bridging the "pharma-startup gap." PharmStars provides startups with education and mentoring to help them engage with pharma as clients and partners. - November 03, 2021 - PharmStars
Cord for Life®, Inc. Announces Cord Blood Clinical Trial Phase I Trial for the Treatment of Lower Back Pain of the Sacroiliac Joint
Cord for Life®, a full-service cord blood bank with over 25 years of experience, today announced plans to conduct a clinical trial to treat lower back pain arising from the Sacroiliac Joint (SIJ) using a biological therapeutic derived from umbilical cord blood. The company has received FDA... - October 29, 2021 - Cord For Life
Pascal Biosciences Announces Financing
Pascal Biosciences Inc. (“Pascal” or the “Company”) (TSXV: PAS) (OTC: PSCBF) (FSE: 6PB-FF) is pleased to announce a non-brokered private placement financing of up to 9,000,000 units (each a “Unit”) of securities at a price of $0.10 per Unit for aggregate gross proceeds of up to $900,000.00 (the “Offering”). - October 29, 2021 - Pascal Biosciences
OmeCare and Hillsborough City School District Renew Partnership for Student and Faculty COVID-19 PCR Testing
Partnership helps district ensure safety standards and meet COVID-19 testing protocols for the 2021-2022 school year. - October 16, 2021 - OmeCare
NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke
NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small Business Technology Transfer (STTR) grant from the National Institute of Neurological Disorders and Stroke (NINDS) under award number R41NS124450. STTR programs are highly competitive programs that... - October 12, 2021 - NuvOx Therapeutics
Omni-HC Selected to Participate in “Audience Amplification” Workshop at Prestigious Global Medical Affairs Meeting
Omni Healthcare Communications has been selected by the Medical Affairs Professional Society to convene a workshop on scientific communication amplification at the MAPS 2022 Global Annual Meeting. - October 02, 2021 - Sunny Ayr Holdings
OmeCare and LifeSite Announce COVID-19 Testing Solution Partnership
The partnership provides a turnkey approach for workplaces, schools, major conventions and other group events looking to ensure safety and meet governmental mandates for students, staff, employees and event participants. - October 01, 2021 - OmeCare
Cayman Chemical Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration
The National Institute of Dental and Craniofacial Research has awarded Cayman Chemical with a $1,700,500 grant to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage... - September 19, 2021 - Cayman Chemical Company
AdvantaPure(R) Announces Fall Trade Show Appearances - Includes Events in the Northeast U.S.
AdvantaPure, the high purity division of NewAge Industries, will exhibit its silicone and TPE tubing and molded assemblies at the ISPE Boston Show, BioProcess International 2021, and Interphex, all taking place in September and October. AdvantaPure will also highlight its recent clean room expansion and its in-process building renovation at the events. The company is increasing its tubing manufacturing capacity to help meet demand for its Single-Use products. - September 16, 2021 - AdvantaPure
Clean-Label Micellar Water Formulation Banishes Trace Chemicals and Outperforms Leading Brand
Locus Performance Ingredients and Genomatica introduce sustainable, natural cleanser featuring Ferma® S sophorolipids and Brontide® natural butylene glycol that eliminates chemical additives and outperforms the current leading brand. The next-generation micellar water replaces controversial legacy ingredients with plant-derived ingredients that provide all the traditional micellar water benefits, but with superior functionality and sustainability. - September 11, 2021 - Locus Performance Ingredients
Mirror Biologics, Inc. Announces Initial Clearance for Phase II/III Clinical Trial (ALIVE) in Advanced Liver Cancer
Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccine immunotherapy for cancer and infectious diseases where... - September 10, 2021 - Mirror Biologics, Inc.
Globally Recognized Agricultural Leader to Become First N.C. PSI Director
Adrian Percy, one of the world’s top leaders in the agriculture field, is set to become the first executive director of the North Carolina Plant Sciences Initiative (N.C. PSI): a world-class research and innovation effort that is poised to solve some of the world’s grandest agricultural... - September 09, 2021 - North Carolina Plant Sciences Initiative
Locus Performance Ingredients Launches New Biosurfactant-Based Personal Care Formulations to Ease Adoption of Clean Label Trend
Ready-to-use formulations utilizing novel Ferma® S sophorolipids help CPG companies replace commonly used surfactants, boost product performance and maximize sustainability. - September 09, 2021 - Locus Performance Ingredients
NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts the Efficacy of Immunotherapy in a Mouse Model of Triple Negative Breast Cancer
NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. Triple negative breast cancer (TNBC) is a particularly deadly form of... - September 09, 2021 - NuvOx Therapeutics
Scientists at AbboMax, Inc. Developed the New Panels of Monoclonal Antibodies to Study B- and T-Cell Lymphomas
Lymphoma is a malignant transformation of either B or T cells or their subtypes. All lymphoma subtypes combined are the seventh most common cancer in the United States. The B-cell lymphomas are types of lymphoma affecting B cells. About 85% of lymphomas are of B-cell origin. T-cell lymphomas are lymphomas that affect T cells. AbboMax has developed the new panels of monoclonal antibodies to study B- and T-cell lymphomas. - September 03, 2021 - AbboMax, Inc.
Defined Bioscience Licenses FGF2-STAB (G3) for Use in Stem Cell Media
Defined recently concluded a licensing agreement with Czech Republic-based Enantis for global use of Enantis’ patented FGF2-STAB® technology both alone and in stem cell media formulations. FGF2-STAB®, originally coined FGF2-G3, was developed by Enantis and Masaryk University, using... - August 30, 2021 - Defined Bioscience Inc.
Locus Performance Ingredients Forms Industry-Leading Advisory Board to Accelerate Global Use of Biosurfactant Innovations
The panel of top CPG and entrepreneurial executives will drive adoption of sustainable biosurfactant ingredients in product formulations. - August 26, 2021 - Locus Performance Ingredients
Omni Healthcare Communications & Res Consortium Form Alliance to Expand Medical Affairs Capabilities
Omni Healthcare Communications (Omni-HC), a US based medical communications firm delivering solutions for today’s scientific exchange challenges, is pleased to announce the formation of a strategic alliance with Res Consortium (Res) of the United Kingdom, a cross-sector leader in digital... - August 21, 2021 - Sunny Ayr Holdings
Reverie Psychedelics and Indiana Health Group Partner to Develop World-Class Psychedelic Research Center
Reverie Psychedelics (Reverie), a leading and rapidly growing psychedelic – assisted psychotherapy clinic and research organization, has further expanded its footprint and capabilities by partnering with Indiana Health Group (IHG), the largest provider of psychiatric and mental health and... - August 05, 2021 - Reverie Psychedelics
Foxx Life Sciences Celebrates Major Expansion
Foxx Life Sciences celebrates two new manufacturing facilities in Londonderry, New Hampshire and Hyderabad, India. The new locations add four additional SUT (Single Use Technologies) Cleanrooms that will allow Foxx to meet the high demands of their biotechnology and biopharmaceutical customers. New... - August 04, 2021 - Foxx Life Sciences
NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM in Ischemic Stroke
NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke. Stroke affects nearly 800,000 patients each year in the US. It is the fourth leading cause of death in this... - July 29, 2021 - NuvOx Therapeutics
NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer Utilizing Lead Drug Candidate NanO2TM
NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has further expanded its patent portfolio in oxygen therapeutics with the issuance of US Patent No. 10946097, “Fractionated radiotherapy and chemotherapy with an oxygen therapeutic,” describing... - July 23, 2021 - NuvOx Therapeutics
Microvascular Therapeutics Has Received Funds from the National Heart, Lung and Blood Institute (NHLBI)
Microvascular Therapeutics (MVT) has received funds from the from the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health for its program to treat cardiovascular disease, which kills more Americans than any other disease. As a leader in fluorocarbon... - July 19, 2021 - Microvascular Therapeutics, Inc.
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase I/II Universal Viral Vaccine Clinical Trial (ALLOPRIME) in Healthy Adults Over 65 Years Old
Mirror Biologics, Inc, (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ vaccines for cancer and infectious diseases where the active... - July 14, 2021 - Mirror Biologics, Inc.
Mirror Biologics, Inc. Announces Initiation of AlloStim® Phase IIB Clinical Trial (STIMVAX) in Patients with Metastatic Colorectal Cancer
Mirror Biologics, Inc. (“Mirror Biologics” or the “Company”), a clinical stage immunotherapy company specializing in the development, manufacturing and clinical translation of next generation therapeutic in-situ cancer vaccines in which the active ingredients are living... - July 09, 2021 - Mirror Biologics, Inc.
Parvus Therapeutics Announces CEO, Senior Executive, and Board of Directors Appointments
Appoints CEO, Senior Executive, and Board of Directors: Peter M. Strumph, Chief Executive Officer; Brendan Classon PhD, Executive Vice President, Research and Development; Louis Demers, Vice President of Technical Operations; Matthew J. Hogan, member of the Board of Directors - July 06, 2021 - Parvus Therapeutics U.S., Inc.
Defined Bioscience Launches with $1.5M SBIR from the NIH to Advance Stem Cell Media
Defined recently received a $1.5M in Phase II SBIR award from the National Institutes of Health to develop defined media over the next two years. - July 03, 2021 - Defined Bioscience Inc.
Pepex Biomedical Receives Approval on a Series of Critical New Patents
Worldwide approval grants the Company exclusivity on a number of methods and manufacturing processes associated with its novel electrochemical biosensors. - July 01, 2021 - Pepex Biomedical, Inc.
GRG Announces 2021 Regenerative Medicine Congress in Dubai UAE
The 2nd Global Regenerative Medicine Congress will be held in Dubai 9-11 September 2021. Registration is now open. Global Regenerative Academy is a world-renowned medical society scientifically studying the clinical application of biological products in the human body. Regenerative Medicine treatments using biological products have been used to slow down the natural aging process, treat a variety of pathologies and improve the quality of life of patients. - June 28, 2021 - Global Regenerative Group
Paras Biopharmaceuticals Finland Oy Named as One of the Top Pharma Outsourcing Companies in Europe 2021
Paras Biopharmaceuticals Highlights Company Innovations that Decode and Create Biologics Medicines for Unmet Medical Needs (Pharma Tech Outlook, USA) - June 22, 2021 - Paras Biopharmaceuticals Finland Oy
Targeted Pharmaceuticals and George Mason University Announce First-Ever Preclinical Study Using Cannabinoids in an Organoid Model
Study Examines the Effects of Cannabinoids Treating Central Nervous System (CNS) Viruses including HIV Associated Dementia - June 16, 2021 - Targeted Pharmaceuticals
Locus Performance Ingredients Launches Amphi™ M: The Next Generation of Biosurfactants for Household and Industrial Formulations
TSCA-approved sophorolipid is customized to offer safe, green replacements to legacy surfactants with unmatched efficacy. - June 11, 2021 - Locus Performance Ingredients
Canada’s Leader in Cannabis Genetics Enters Medical Market
Apollo Green, Canada’s leader in cannabis genetics, announced its entry into the medical marijuana sales with unique strains of cannabis not commonly available in the Canadian marketplace. The importance of having available alternatives for pain management cannot be understated. Studies have recently shown the link between cannabis availability and reduced use of opioids. Three specialty strains of plants and seven strains of seeds will be available in Ontario, Canada. - June 08, 2021 - Apollo Green
Thrivous Launches Omega Cardioprotector Formula 2
Thrivous, the human enhancement company, has released Omega Cardioprotector Formula 2. Omega is an advanced geroprotector supplement that Thrivous develops to enhance heart function and circulation for better aging. Omega formula 2 combines geroprotector nutrients with the highest levels of... - June 03, 2021 - Thrivous
ALS TDI Launches New Young Faces of ALS Program
The ALS Therapy Development Institute's Young Faces of ALS program spreads awareness about the impact that ALS can have on young people; launch coincides with MLB's inaugural Lou Gehrig Day. - June 02, 2021 - ALS Therapy Development Institute